Cystic Fibrosis Clinical Trials in Birmingham, Alabama

9 studies are recruiting for cystic fibrosis in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

   The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

   Stage

   Not phased

   Ages

   3 to 18

   Site

   The Children's Hospital Alabama & University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   33 in total

   Run by

   University of Washington, the Collaborative Health Studies Coordinating Center

   See if you can join NCT06654752 on ClinicalTrials.gov

2. Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

   This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).

   Stage

   Not phased

   Ages

   Up to 10

   Site

   The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   35 in total

   Run by

   Sonya Heltshe

   See if you can join NCT04509050 on ClinicalTrials.gov

3. Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

   The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs me…

   Stage

   Phase 4

   Ages

   6 and older

   Site

   The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   60 in total

   Run by

   Chris Goss

   See if you can join NCT05548283 on ClinicalTrials.gov

4. Rare CFTR Mutation Cell Collection Protocol (RARE)

   Over 1,900 mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein are implicated in causing Cystic Fibrosis (CF). Potential therapies that directly target defective CFTR are being evaluated in important clinical trials, but most target the most common CFTR …

   Stage

   Not phased

   Ages

   17 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   George Solomon

   See if you can join NCT03161808 on ClinicalTrials.gov

5. Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)

   Nutrition and body composition, the amount of muscle and fat in the body, has a role in overall health. This study wants to learn more about how nutrition and body composition affects health outcomes like glucose tolerance and lung function in patients with cystic fibrosis (CF) who are ages 16-30 y…

   Stage

   Not phased

   Ages

   16 and older

   Site

   University of Alabama at Birmingham (UAB)/Children's of Alabama, Birmingham, Alabama

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT04002882 on ClinicalTrials.gov

6. Personalized Theratyping Trial

   The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

   Stage

   EARLY_Phase 1

   Ages

   6 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   George Solomon

   See if you can join NCT03587961 on ClinicalTrials.gov

7. Health Outcomes of Parents With Cystic Fibrosis-Aim 2

   The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators. The investigators will collect physical and mental health data to comprehensively evaluate the im…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama-Birmingham, Birmingham, Alabama

   Locations

   18 in total

   Run by

   University of Pittsburgh

   See if you can join NCT06296394 on ClinicalTrials.gov

8. Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

   RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor …

   Stage

   Not phased

   Ages

   6 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   18 in total

   Run by

   Boston Children's Hospital

   See if you can join NCT06683092 on ClinicalTrials.gov

9. A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

   The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to in…

   Stage

   Not phased

   Ages

   12 and older

   Site

   The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   68 in total

   Run by

   Nicole Hamblett

   See if you can join NCT06504589 on ClinicalTrials.gov